Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from ReShape Lifesciences ( (RSLS) ).
On February 15, 2025, ReShape Lifesciences announced a Securities Purchase Agreement to issue and sell 2,575,107 shares of common stock and accompanying warrants to investors at a price of $2.33 per unit, resulting in gross proceeds of approximately $6.0 million. The proceeds will be used for general corporate purposes, including the company’s proposed merger with Vyome Therapeutics and asset sale to Ninjour Health. The offering, managed by Maxim Group LLC as the exclusive placement agent, closed on February 18, 2025, and involves warrants with various exercise conditions and adjustments based on future shareholder approvals.
More about ReShape Lifesciences
ReShape Lifesciences is a leading American company in the weight loss and metabolic health sector, providing an array of proven products and services aimed at managing and treating obesity and metabolic diseases. The company offers FDA-approved systems like the Lap-Band, which are minimally invasive alternatives to traditional weight loss surgeries, and innovative technologies such as the ReShape Diabetes Neuromodulation system and Obalon balloon technology.
YTD Price Performance: -70.18%
Average Trading Volume: 800,180
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $788.4K
See more data about RSLS stock on TipRanks’ Stock Analysis page.
